Ventaleon founder Dr. Gerhard Scheuch receives Juraj Ferin Award 2017 for outstanding contributions to the International Society for Aerosols in Medicine

Gemuenden, Germany, June 14, 2017– Ventaleon GmbH, a biotechnology company focusing
on the development of inhaled treatments against viral infections, is pleased to congratulate
Dr. Gerhard Scheuch, who has received the Juraj Ferin Award 2017 for his outstanding
contributions to the International Society for Aerosols in Medicine (ISAM). The award was
presented on June 4, 2017 at the 21st ISAM Congress in Santa Fe, New Mexico, USA.

Dr. Scheuch is an internationally recognized expert in pulmonary drug delivery, inhalation
products as well as respiratory diseases and served as ISAM president from 2007 through 2013.
Dr. Scheuch founded Ventaleon in 2012 and was CEO until stepping down earlier this year but
will continue to serve as a member of the Supervisory Board of Ventaleon. He was founder and
CEO of Activaero as well as of Inamed, both companies dedicated to developing inhalation
technologies and therapies, and also served as chief scientific officer at Vectura group plc after
their acquisition of Activaero. He holds a PhD in physics from the Wolfgang Goethe University
Frankfurt (Germany).

For further information, please contact:

Contact
Ventaleon GmbH
Dr. Ulrich Dauer, CEO
Tel.: +49 6453 58530 40
E-Mail: Diese E-Mail-Adresse ist vor Spambots gesch├╝tzt! Zur Anzeige muss JavaScript eingeschaltet sein!

Media Inquiries
MC Services AG
Katja Arnold, Dr. Brigitte Keller
Tel: +49 89 21022 0
E-Mail: Diese E-Mail-Adresse ist vor Spambots gesch├╝tzt! Zur Anzeige muss JavaScript eingeschaltet sein!

About Ventaleon GmbH: www.ventaleon.com

Ventaleon GmbH is a biotechnology company focused on the development of inhaled
treatments against viral infections. The Company’s lead therapy candidate is an inhaled form
of LASAG (D,L-lysine acetylsalicylate • glycine), which it is developing to treat severe influenza.
A proof-of-concept study in influenza patients with moderate to severe symptoms
demonstrated more rapid symptom decline when administered inhaled LASAG compared to
standard of care. The Company is currently preparing to enter a pivotal clinical trial with inhaled
LASAG. Ventaleon was founded as a spin-off from Activaero and is supported by a group of
leading international investors, including Coöperatief LSP U.A,, BioMedInvest II LP, Abalis
Finance AG, Vesalius Biocapital I S.A., Venture Incubator AG, CatheyWorldInvestment Ltd. and
BayBg.